Julie Rathbun
Investor Relations Kontakt bei ATHIRA PHARMA, INC.
Aktive Positionen von Julie Rathbun
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ATHIRA PHARMA, INC. | Investor Relations Kontakt | - | - |
Public Communications Contact | - | - | |
Rathbun Communications, Inc. | Gründer | 01.01.2004 | - |
Präsident | 01.01.2004 | - |
Karriereverlauf von Julie Rathbun
Ehemalige bekannte Positionen von Julie Rathbun
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
IMMUNE DESIGN CORP | Public Communications Contact | - | 02.04.2019 |
NEUROGENE INC. | Public Communications Contact | - | - |
SAREPTA THERAPEUTICS, INC. | Public Communications Contact | - | - |
Ausbildung von Julie Rathbun
Western Washington University | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 7 |
Operativ
Public Communications Contact | 4 |
Founder | 1 |
President | 1 |
Sektoral
Health Technology | 5 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
SAREPTA THERAPEUTICS, INC. | Health Technology |
ATHIRA PHARMA, INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Immune Design Corp.
Immune Design Corp. Pharmaceuticals: MajorHealth Technology Immune Design Corp. is a clinical-stage immunotherapy company focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. It develops multiple product candidates from its discovery platforms, ZVex and GLAAS. The company was founded by Steven G. Reed and David Baltimore on February 20, 2008 and is headquartered in Kenilworth, NJ. | Health Technology |
Neoleukin Therapeutics, Inc.
Neoleukin Therapeutics, Inc. BiotechnologyHealth Technology Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA. | Health Technology |
Rathbun Communications, Inc. |
- Börse
- Insiders
- Julie Rathbun
- Erfahrung